알레르기성 비염 치료제 시장(2024-2034년)

The global Allergic Rhinitis Drugs market is estimated to grow at a CAGR of 2.7% by 2034

The Allergic Rhinitis Drugs Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Prevalence of Allergic Rhinitis

Allergic rhinitis, often referred to as hay fever, is an increasing global issue that impacts millions of individuals, significantly influencing their overall quality of life. The increasing prevalence of allergic rhinitis has not only led to a surge in healthcare costs but has also emerged as a significant market driver.

There has been a notable increase in the pharmaceutical industry's demand for medications aimed at relieving symptoms associated with allergic rhinitis. Antihistamines, decongestants, corticosteroids, and allergy immunotherapy are among the widely prescribed drugs, contributing to a booming market for allergy medications. Nasal sprays and other medical devices designed to provide relief from allergic rhinitis symptoms have gained popularity. These devices provide a non-pharmacological method for symptom management, creating an expanding market for cutting-edge technologies.

The increasing prevalence of allergic rhinitis has led to a higher demand for healthcare services, including allergy testing and immunotherapy. Allergists, immunologists, and ENT specialists are witnessing an uptick in patient visits, driving growth in these medical fields. The rise of telemedicine has provided a convenient platform for allergic rhinitis patients to consult healthcare professionals remotely. This trend has not only improved access to care but has also contributed to the expansion of virtual healthcare services.

Growing Awareness and Diagnosis Driving Allergic Rhinitis Drugs Market

As information becomes more accessible, patients are increasingly becoming proactive advocates for their health. The internet, social media, and healthcare apps play a pivotal role in disseminating knowledge about various health conditions, symptoms, and preventive measures. This empowerment has led to a more informed patient population, actively participating in their healthcare decisions. Growing awareness has shifted the focus from reactive to proactive healthcare. Individuals are now more inclined towards preventive measures, including regular health check-ups, screenings, and lifestyle modifications. This shift has not only reduced the burden on healthcare systems but has also created new market opportunities for preventive healthcare services and products. The health and wellness industry is booming as people increasingly prioritize a holistic approach to well-being. From fitness trackers and nutrition apps to wellness retreats and personalized health plans, the market is witnessing unprecedented growth.

Individuals are prepared to invest in products and services that enhance their overall well-being and quality of life. The swift progress of diagnostic technologies has transformed the precision and efficiency of disease identification.

From genetic testing to advanced imaging techniques, these technologies enable early detection and personalized treatment plans, driving demand for diagnostic services and equipment.

The increasing comprehension of the genetic and molecular dimensions of diseases has opened the door to precision medicine. Customizing treatments based on individual genetic profiles enables more efficient and targeted interventions. This shift in paradigm is shaping pharmaceutical development, emphasizing personalized therapies. Greater awareness has resulted in a rise in the demand for regular screenings and early detection programs.

What Questions Should You Ask before Buying a Market Research Report?

How is the Allergic Rhinitis Drugs Market evolving?

What is driving and restraining the Allergic Rhinitis Drugs Market?

How will each Allergic Rhinitis Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each Allergic Rhinitis Drugs submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading Allergic Rhinitis Drugs Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the Allergic Rhinitis Drugs projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of Allergic Rhinitis

Drugs projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the Allergic Rhinitis Drugs Market?

Where is the Allergic Rhinitis Drugs Market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Allergic Rhinitis Drugs Market today, and over the next 10 years:

Our 322-page report provides 120 tables and 200 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Allergic Rhinitis Drugs Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges) and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

By Treatment Type

Antihistamines

Immunotherapy: Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT)

Corticosteroids

Decongestants

Others

By Disease Type

Seasonal Allergic Rhinitis

Perennial Allergic Rhinitis

Occupational Allergic Rhinitis

By Drug

Prescription

OTC

By Route of Administration

Oral

Nasal

Intraocular

Intravenous

By Distribution channel

Hospital Pharmacies

Retail Pharmacies

Online channels

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 26 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Russia

Poland

Belgium

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Singapore

Taiwan

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Allergic Rhinitis Drugs Market 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

Alcon

AstraZeneca

Bayer AG

Boehringer Ingelheim International GmbH

Dr. Reddy's Laboratories Ltd.

GSK plc

Johnson & Johnson Services, Inc.

Merck & Co., Inc.

Sanofi

Sun Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.

Overall world revenue for Allergic Rhinitis Drugs Market, 2024 to 2034 in terms of value the market will surpass US$16,800.0 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Allergic Rhinitis Drugs Market 2024 to 2034 report help you?

In summary, our 320+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Allergic Rhinitis Drugs Market 2024 to 2034 Market, with forecasts for product and application each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 26 key national markets - See forecasts for the Allergic Rhinitis Drugs Market, 2024 to 2034 in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 11 of the major companies involved in the Allergic Rhinitis Drugs Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Allergic Rhinitis Drugs Market 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Allergic Rhinitis Drugs
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
  • 3.2.1 Market Driving Factors
    • 3.2.1.1 Growing Awareness About Allergies and Available Treatment Options
    • 3.2.1.2 Increasing Prevalence of Respiratory Disorders
    • 3.2.1.3 Launch of Effective and Novel Drug Delivery Systems
    • 3.2.1.4 Technological Advancements
    • 3.2.1.5 Growing Pollution Levels Coupled with Rise in Respiratory Disorders
  • 3.2.2 Market Restraining Factors
    • 3.2.2.1 Adverse Effects of Drugs Used in Treatment of Allergic Rhinitis
    • 3.2.2.2 Similarity of Symptoms with Other Diseases
  • 3.2.3 Market Opportunities
    • 3.2.3.1 Increasing Advancements in Allergen Immunotherapy (AIT)
    • 3.2.3.2 Favourable Government Initiatives to Promote Awareness Regarding Allergic Rhinitis
• 3.3 COVID-19 Impact Analysis
• 3.4 Porter's Five Forces Analysis
  • 3.4.1 Bargaining Power of Suppliers
  • 3.4.2 Bargaining Power of Buyers
  • 3.4.3 Competitive Rivalry
  • 3.4.4 Threat from Substitutes
  • 3.4.5 Threat of New Entrants
• 3.5 PEST Analysis

4 Allergic Rhinitis Drugs Analysis by Treatment Type

• 4.1 Key Findings
• 4.2 Treatment Type Segment: Market Attractiveness Index
• 4.3 Allergic Rhinitis Drugs Size Estimation and Forecast by Treatment Type
• 4.4 Antihistamines
  • 4.4.1 Market Size by Region, 2024-2034 (US$ Million)
  • 4.4.2 Market Share by Region, 2024 & 2034 (%)
• 4.5 Immunotherapy
  • 4.5.1 Market Size by Region, 2024-2034 (US$ Million)
  • 4.5.2 Market Share by Region, 2024 & 2034 (%)
    • 4.5.2.1 Subcutaneous Immunotherapy (SCIT)
    • 4.5.2.2 Sublingual Immunotherapy (SLIT)
• 4.6 Corticosteroids
  • 4.6.1 Market Size by Region, 2024-2034 (US$ Million)
  • 4.6.2 Market Share by Region, 2024 & 2034 (%)
• 4.7 Decongestants
  • 4.7.1 Market Size by Region, 2024-2034 (US$ Million)
  • 4.7.2 Market Share by Region, 2024 & 2034 (%)
• 4.8 Others
  • 4.8.1 Market Size by Region, 2024-2034 (US$ Million)
  • 4.8.2 Market Share by Region, 2024 & 2034 (%)

5 Allergic Rhinitis Drugs Analysis by Disease Type

• 5.1 Key Findings
• 5.2 Disease Type Segment: Market Attractiveness Index
• 5.3 Allergic Rhinitis Drugs Size Estimation and Forecast by Disease Type
• 5.4 Seasonal Allergic Rhinitis
  • 5.4.1 Market Size by Region, 2024-2034 (US$ Million)
  • 5.4.2 Market Share by Region, 2024 & 2034 (%)
• 5.5 Perennial Allergic Rhinitis
  • 5.5.1 Market Size by Region, 2024-2034 (US$ Million)
  • 5.5.2 Market Share by Region, 2024 & 2034 (%)
• 5.6 Occupational Allergic Rhinitis
  • 5.6.1 Market Size by Region, 2024-2034 (US$ Million)
  • 5.6.2 Market Share by Region, 2024 & 2034 (%)

6 Allergic Rhinitis Drugs Analysis by Drug Type

• 6.1 Key Findings
• 6.2 Drug Type Segment: Market Attractiveness Index
• 6.3 Allergic Rhinitis Drugs Size Estimation and Forecast by Drug Type
• 6.4 Prescription
  • 6.4.1 Market Size by Region, 2024-2034 (US$ Million)
  • 6.4.2 Market Share by Region, 2024 & 2034 (%)
• 6.5 OTC
  • 6.5.1 Market Size by Region, 2024-2034 (US$ Million)
  • 6.5.2 Market Share by Region, 2024 & 2034 (%)

7 Allergic Rhinitis Drugs Analysis by Route of Administration

• 7.1 Key Findings
• 7.2 Route of Administration Segment: Market Attractiveness Index
• 7.3 Allergic Rhinitis Drugs Size Estimation and Forecast by Route of Administration
• 7.4 Oral
  • 7.4.1 Market Size by Region, 2024-2034 (US$ Million)
  • 7.4.2 Market Share by Region, 2024 & 2034 (%)
• 7.5 Nasal
  • 7.5.1 Market Size by Region, 2024-2034 (US$ Million)
  • 7.5.2 Market Share by Region, 2024 & 2034 (%)
• 7.6 Intraocular
  • 7.6.1 Market Size by Region, 2024-2034 (US$ Million)
  • 7.6.2 Market Share by Region, 2024 & 2034 (%)
• 7.7 Intravenous
  • 7.7.1 Market Size by Region, 2024-2034 (US$ Million)
  • 7.7.2 Market Share by Region, 2024 & 2034 (%)

8 Allergic Rhinitis Drugs Analysis by Distribution Channel

• 8.1 Key Findings
• 8.2 Distribution Channel Segment: Market Attractiveness Index
• 8.3 Allergic Rhinitis Drugs Size Estimation and Forecast by Distribution Channel
• 8.4 Retail Pharmacies
  • 8.4.1 Market Size by Region, 2024-2034 (US$ Million)
  • 8.4.2 Market Share by Region, 2024 & 2034 (%)
• 8.5 Hospital Pharmacies
  • 8.5.1 Market Size by Region, 2024-2034 (US$ Million)
  • 8.5.2 Market Share by Region, 2024 & 2034 (%)
• 8.6 Online Channels
  • 8.6.1 Market Size by Region, 2024-2034 (US$ Million)
  • 8.6.2 Market Share by Region, 2024 & 2034 (%)

9 Allergic Rhinitis Drugs Analysis by Region

• 9.1 Key Findings
• 9.2 Regional Market Size Estimation and Forecast

10 North America Allergic Rhinitis Drugs Analysis

• 10.1 Key Findings
• 10.2 North America Allergic Rhinitis Drugs Attractiveness Index
• 10.3 North America Allergic Rhinitis Drugs by Country, 2024, 2029 & 2034 (US$ Million)
• 10.4 North America Allergic Rhinitis Drugs Size Estimation and Forecast by Country
• 10.5 North America Allergic Rhinitis Drugs Size Estimation and Forecast by Treatment Type
• 10.6 North America Allergic Rhinitis Drugs Size Estimation and Forecast by Disease Type
• 10.7 North America Allergic Rhinitis Drugs Size Estimation and Forecast by Drug
• 10.8 North America Allergic Rhinitis Drugs Size Estimation and Forecast by Route of Administration
• 10.9 North America Allergic Rhinitis Drugs Size Estimation and Forecast by Distribution Channel
• 10.10 U.S. Allergic Rhinitis Drugs Analysis
• 10.11 Canada Allergic Rhinitis Drugs Analysis

11 Europe Allergic Rhinitis Drugs Analysis

• 11.1 Key Findings
• 11.2 Europe Allergic Rhinitis Drugs Attractiveness Index
• 11.3 Europe Allergic Rhinitis Drugs by Country, 2024, 2029 & 2034 (US$ Million)
• 11.4 Europe Allergic Rhinitis Drugs Size Estimation and Forecast by Country
• 11.5 Europe Allergic Rhinitis Drugs Size Estimation and Forecast by Treatment Type
• 11.6 Europe Allergic Rhinitis Drugs Size Estimation and Forecast by Disease Type
• 11.7 Europe Allergic Rhinitis Drugs Size Estimation and Forecast by Drug Type
• 11.8 Europe Allergic Rhinitis Drugs Size Estimation and Forecast by Route of Administration
• 11.9 Europe Allergic Rhinitis Drugs Size Estimation and Forecast by Distribution Channel
• 11.10 Germany Allergic Rhinitis Drugs Analysis
• 11.11 France Allergic Rhinitis Drugs Analysis
• 11.12 UK Allergic Rhinitis Drugs Analysis
• 11.13 Italy Allergic Rhinitis Drugs Analysis
• 11.14 Spain Allergic Rhinitis Drugs Analysis
• 11.15 Russia Allergic Rhinitis Drugs Analysis
• 11.16 Poland Allergic Rhinitis Drugs Analysis
• 11.17 Belgium Allergic Rhinitis Drugs Analysis
• 11.18 Rest of Europe Allergic Rhinitis Drugs Analysis

12 Asia Pacific Allergic Rhinitis Drugs Analysis

• 12.1 Key Findings
• 12.2 Asia Pacific Allergic Rhinitis Drugs Attractiveness Index
• 12.3 Asia Pacific Allergic Rhinitis Drugs by Country, 2024, 2029 & 2034 (US$ Million)
• 12.4 Asia Pacific Allergic Rhinitis Drugs Size Estimation and Forecast by Country
• 12.5 Asia Pacific Allergic Rhinitis Drugs Size Estimation and Forecast by Treatment Type
• 12.6 Asia Pacific Allergic Rhinitis Drugs Size Estimation and Forecast by Disease Type
• 12.7 Asia Pacific Allergic Rhinitis Drugs Size Estimation and Forecast by Drug Type
• 12.8 Asia Pacific Allergic Rhinitis Drugs Size Estimation and Forecast by Route of Administration
• 12.9 Asia Pacific Allergic Rhinitis Drugs Size Estimation and Forecast by Distribution Channel
• 12.10 Japan Allergic Rhinitis Drugs Analysis
• 12.11 China Allergic Rhinitis Drugs Analysis
• 12.12 India Allergic Rhinitis Drugs Analysis
• 12.13 Australia Allergic Rhinitis Drugs Analysis
• 12.14 South Korea Allergic Rhinitis Drugs Analysis
• 12.15 Singapore Allergic Rhinitis Drugs Analysis
• 12.16 Taiwan Allergic Rhinitis Drugs Analysis
• 12.17 Rest of Asia Pacific Allergic Rhinitis Drugs Analysis

13 Latin America Allergic Rhinitis Drugs Analysis

• 13.1 Key Findings
• 13.2 Latin America Allergic Rhinitis Drugs Attractiveness Index
• 13.3 Latin America Allergic Rhinitis Drugs by Country, 2024, 2029 & 2034 (US$ Million)
• 13.4 Latin America Allergic Rhinitis Drugs Size Estimation and Forecast by Country
• 13.5 Latin America Allergic Rhinitis Drugs Size Estimation and Forecast by Treatment Type
• 13.6 Latin America Allergic Rhinitis Drugs Size Estimation and Forecast by Disease Type
• 13.7 Latin America Allergic Rhinitis Drugs Size Estimation and Forecast by Drug Type
• 13.8 Latin America Allergic Rhinitis Drugs Size Estimation and Forecast by Route of Administration
• 13.9 Latin America Allergic Rhinitis Drugs Size Estimation and Forecast by Distribution Channel
• 13.10 Brazil Allergic Rhinitis Drugs Analysis
• 13.11 Mexico Allergic Rhinitis Drugs Analysis
• 13.12 Argentina Allergic Rhinitis Drugs Analysis
• 13.13 Rest of Latin America Allergic Rhinitis Drugs Analysis

14 MEA Allergic Rhinitis Drugs Analysis

• 14.1 Key Findings
• 14.2 MEA Allergic Rhinitis Drugs Attractiveness Index
• 14.3 MEA Allergic Rhinitis Drugs by Country, 2024, 2029 & 2034 (US$ Million)
• 14.4 MEA Allergic Rhinitis Drugs Size Estimation and Forecast by Country
• 14.5 MEA Allergic Rhinitis Drugs Size Estimation and Forecast by Treatment Type
• 14.6 MEA Allergic Rhinitis Drugs Size Estimation and Forecast by Disease Type
• 14.7 MEA Allergic Rhinitis Drugs Size Estimation and Forecast by Drug Type
• 14.8 MEA Allergic Rhinitis Drugs Size Estimation and Forecast by Route of Administration
• 14.9 MEA Allergic Rhinitis Drugs Size Estimation and Forecast by Distribution Channel
• 14.10 GCC Allergic Rhinitis Drugs Analysis
• 14.11 South Africa Allergic Rhinitis Drugs Analysis
• 14.12 Rest of MEA Allergic Rhinitis Drugs Analysis

15 Company Profiles

• 15.1 Competitive Landscape, 2023
• 15.2 Strategic Outlook
• 15.3 Alcon
  • 15.3.1 Company Snapshot
  • 15.3.2 Company Overview
  • 15.3.3 Financial Analysis
    • 15.3.3.1 Net Revenue, 2017-2022
    • 15.3.3.2 R&D, 2017-2022
    • 15.3.3.3 Regional Market Shares, 2022
  • 15.3.4 Product Benchmarking
  • 15.3.5 Strategic Outlook
• 15.4 AstraZeneca
  • 15.4.1 Company Snapshot
  • 15.4.2 Company Overview
  • 15.4.3 Financial Analysis
    • 15.4.3.1 Net Revenue, 2017-2022
    • 15.4.3.2 R&D, 2017-2022
    • 15.4.3.3 Regional Market Shares, 2022
  • 15.4.4 Product Benchmarking
  • 15.4.5 Strategic Outlook
• 15.5 Bayer AG
  • 15.5.1 Company Snapshot
  • 15.5.2 Company Overview
  • 15.5.3 Financial Analysis
    • 15.5.3.1 Net Revenue, 2017-2022
    • 15.5.3.2 R&D, 2017-2022
    • 15.5.3.3 Regional Market Shares, 2022
  • 15.5.4 Product Benchmarking
  • 15.5.5 Strategic Outlook
• 15.6 Boehringer Ingelheim International GmbH
  • 15.6.1 Company Snapshot
  • 15.6.2 Company Overview
  • 15.6.3 Financial Analysis
    • 15.6.3.1 Net Revenue, 2017-2022
    • 15.6.3.2 R&D, 2017-2022
    • 15.6.3.3 Regional Market Shares, 2022
  • 15.6.4 Product Benchmarking
• 15.7 Dr. Reddy's Laboratories Ltd.
  • 15.7.1 Company Snapshot
  • 15.7.2 Company Overview
  • 15.7.3 Financial Analysis
    • 15.7.3.1 Net Revenue, 2017-2022
    • 15.7.3.2 R&D, 2017-2022
    • 15.7.3.3 Regional Market Shares, 2022
  • 15.7.4 Product Benchmarking
  • 15.7.5 Strategic Outlook
• 15.8 GSK plc
  • 15.8.1 Company Snapshot
  • 15.8.2 Company Overview
  • 15.8.3 Financial Analysis
    • 15.8.3.1 Net Revenue, 2017-2022
    • 15.8.3.2 R&D, 2017-2022
    • 15.8.3.3 Regional Market Shares, 2022
  • 15.8.4 Product Benchmarking
  • 15.8.5 Strategic Outlook
• 15.9 Johnson & Johnson Services, Inc.
  • 15.9.1 Company Snapshot
  • 15.9.2 Company Overview
  • 15.9.3 Financial Analysis
    • 15.9.3.1 Net Revenue, 2017-2022
    • 15.9.3.2 R&D, 2017-2022
    • 15.9.3.3 Regional Market Shares, 2022
  • 15.9.4 Product Benchmarking
  • 15.9.5 Strategic Outlook
• 15.10 Merck & Co., Inc.
  • 15.10.1 Company Snapshot
  • 15.10.2 Company Overview
  • 15.10.3 Financial Analysis
    • 15.10.3.1 Net Revenue, 2017-2022
    • 15.10.3.2 R&D, 2017-2022
    • 15.10.3.3 Regional Market Shares, 2022
  • 15.10.4 Product Benchmarking
  • 15.10.5 Strategic Outlook
• 15.11 Sanofi
  • 15.11.1 Company Snapshot
  • 15.11.2 Company Overview
  • 15.11.3 Financial Analysis
    • 15.11.3.1 Net Revenue, 2017-2022
    • 15.11.3.2 R&D, 2017-2022
    • 15.11.3.3 Regional Market Shares, 2022
  • 15.11.4 Product Benchmarking
  • 15.11.5 Strategic Outlook
• 15.12 Sun Pharmaceutical Industries Ltd.
  • 15.12.1 Company Snapshot
  • 15.12.2 Company Overview
  • 15.12.3 Financial Analysis
    • 15.12.3.1 Net Revenue, 2017-2022
    • 15.12.3.2 R&D, 2017-2022
    • 15.12.3.3 Regional Market Shares, 2022
  • 15.12.4 Product Benchmarking
  • 15.12.5 Strategic Outlook
• 15.13 Teva Pharmaceutical Industries Ltd.
  • 15.13.1 Company Snapshot
  • 15.13.2 Company Overview
  • 15.13.3 Financial Analysis
    • 15.13.3.1 Net Revenue, 2017-2022
    • 15.13.3.2 R&D, 2017-2022
    • 15.13.3.3 Regional Market Shares, 2022
  • 15.13.4 Product Benchmarking
  • 15.13.5 Strategic Outlook

16 Conclusion and Recommendations

• 16.1 Concluding Remarks from Visiongain
• 16.2 Recommendations for Market Players